<DOC>
	<DOCNO>NCT03042325</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy alogliptin tablet give monotherapy add therapy participant standard care management Type 2 Diabetes Mellitus ( T2DM ) .</brief_summary>
	<brief_title>Safety Efficacy Alogliptin Indian Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The drug test study call alogliptin . Alogliptin test treat people Type 2 Diabetes Mellitus ( T2DM ) . This study look side effect glycemic control people take alogliptin addition standard care . The study enroll approximately 300 patient . All participant receive alogliptin tablet dose determine base creatinine clearance . The recommend dose alogliptin 25 mg daily normal mildly impaired renal function ( creatinine clearance [ CrCl ] ≥60 mL/min ) , dose 12.5 mg participant moderate renal impairment ( CrCl ≥30 &lt; 60 mL/min ) , 6.25 mg participant severe renal impairment ( CrCl ≥15 &lt; 30 mL/min ) . Participants end-stage renal disease ( ESRD ) ( CrCl &lt; 15 mL/min require hemodialysis ) exclude , addition standard care management T2DM . All participant ask take one tablet every morning day throughout study . This multi-center trial conduct India . The overall time participate study 33 week . Participants make multiple visit clinic , contact telephone 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>1 . Participants T2DM dipeptidyl peptidase4 ( DPP4 ) inhibitornaive ; include alogliptin . 1 . Has contraindication limitation administration alogliptin tablet accord approve label/Prescribing Information . 2 . Participants treat alogliptin tablet outside approve label/ prescribe information . 3 . Has endstage renal disease ( ESRD ) ( Creatinine Clearance ( CrCl ) &lt; 15 mL/min require hemodialysis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>